ClinicalTrials.gg
CompletedNCT01204294Updated Mar 28, 2014Results posted

Comprehensive Add on Study in Japan

A Phase 3 interventional study of Linagliptin and Linagliptin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 43 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-03-28.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
574
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
11th of 67
574 · median 175
Started
2010
with 7 others
Phase 3
31 of 67
none open now
Registered
21st of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 8 that started in 2010, is one of 31 in phase 3, and was the 21st registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The objective of the current study is to investigate the safety and efficacy of linagliptin (5mg / once daily) given for 52 weeks as add-on therapy to patients with type 2 diabetes mellitus and insufficient glycaemic control despite diet, exercise, and treatment with one approved antidiabetic drug.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of type 2 diabetes mellitus
  2. Male and female patients on diet and exercise regimen who are treated with one antidiabetic drug

Exclusion criteria

Exclusion criteria:

  1. Myocardial infarction, stroke, , or pulmonary embolism
  2. Impaired hepatic function
  3. Glitazone, glinide, and sulfonylurea group: renal failure or renal impairment defined as estimated \<30 ml/min (severe renal impairment) at Visit 1, Biguanide group: renal failure or renal impairment defined as estimated glomerular filtration rate \<60 ml/min (moderate renal impairment) at Visit 1
  4. Treatment with anti-obesity drugs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
574 participants (actual)

Study arms

  • Experimental
    Bigu+Lina

    biguanide plus linagliptin

    Drug: Linagliptin

  • Experimental
    Glin+Lina

    glinide plus linagliptin

    Drug: Linagliptin

  • Experimental
    Glit+Lina

    glitazone plus linagliptin

    Drug: Linagliptin

  • Experimental
    SU+Lina

    sulfonylurea plus linagliptin

    Drug: Linagliptin

  • Experimental
    A-GI+Lina

    alpha-glucosidase inhibitor plus linagliptin

    Drug: Linagliptin

  • Active comparator
    SU+Met

    sulfonylurea plus metformin

    Drug: Metformin

  • Active comparator
    A-GI+Met

    alpha-glucosidase inhibitor plus metformin

    Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    The number of patient with any AEs, patients with severe AE, patients with AEs leading to discontinuation of trial drug, and patients with Hypoglycaemic events

    Time frame: The first drug administration through 7 days after the last drug administration, up to 382 days

Secondary outcomes

  1. Glycosylated Haemoglobin A1c (HbA1c)

    The change from baseline in HbA1c after 52 weeks of treatment. When the HbA1c after 52 weeks treatment was missing, the value from the measurements at the closest preceding visit replaced the missing value.

    Time frame: Baseline and 52 weeks

07

Results

Posted Jan 23, 2013

Participant flow

A total of 618 patients were enrolled in the trial at 43 trial sites, and 37 patients were withdrawn from the trial because of screening failure. 581 patients were entered into the 2-week placebo run-in period, and 7 patients were withdrawn. 574 patients completed the 2-week placebo run-in period and took linagliptin 5 mg or metformin.

Participant flow — Overall Study
MilestoneBigu+LinaGlin+LinaGlit+LinaSU+LinaA-GI+LinaSU+MetA-GI+Met
Started826674143856361
Completed795869132835859
Not completed38511252
Withdrew: Adverse event2607140
Withdrew: Protocol violation1021000
Withdrew: Withdrawal by subject0221112
Withdrew: Lack of efficacy0002000
Withdrew: Other (house moving)0010000

Outcome measures

PrimaryIncidence of Adverse Events (AEs)

The number of patient with any AEs, patients with severe AE, patients with AEs leading to discontinuation of trial drug, and patients with Hypoglycaemic events

Time frame:
The first drug administration through 7 days after the last drug administration, up to 382 days
Reported as:
Number · Patients
Incidence of Adverse Events (AEs)
PatientsBigu+LinaGlin+LinaGlit+LinaSU+LinaA-GI+LinaSU+MetA-GI+Met
Patients with any AE695562114714452
Patients with severe AE1102110
Patients with AEs leading to discontinuation2508140
Patients with Hypoglycaemic events102212102
SecondaryGlycosylated Haemoglobin A1c (HbA1c)

The change from baseline in HbA1c after 52 weeks of treatment. When the HbA1c after 52 weeks treatment was missing, the value from the measurements at the closest preceding visit replaced the missing value.

Time frame:
Baseline and 52 weeks
Reported as:
Mean · Percentage
Glycosylated Haemoglobin A1c (HbA1c)
PercentageBigu+LinaGlin+LinaGlit+LinaSU+LinaA-GI+LinaSU+MetA-GI+Met
Baseline7.98 ± 0.757.92 ± 0.827.86 ± 0.838.12 ± 0.787.87 ± 0.758.01 ± 0.648.07 ± 1.04
At 52 weeks7.10 ± 0.827.19 ± 0.757.07 ± 0.747.42 ± 0.916.96 ± 0.757.19 ± 0.726.98 ± 0.75
Change from baseline to 52 weeks-0.88 ± 0.64-0.73 ± 0.65-0.79 ± 0.50-0.70 ± 0.70-0.91 ± 0.61-0.82 ± 0.78-1.09 ± 0.87

Adverse events

Collected over The first drug administration through 7 days after the last drug administration, up to 382 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bigu+Lina—8/82 (9.8%)55/82 (67.1%)
Glin+Lina—5/66 (7.6%)41/66 (62.1%)
Glit+Lina—2/74 (2.7%)37/74 (50%)
SU+Lina—7/143 (4.9%)83/143 (58%)
A-GI+Lina—7/85 (8.2%)54/85 (63.5%)
SU+Met—5/63 (7.9%)31/63 (49.2%)
A-GI+Met—3/61 (4.9%)33/61 (54.1%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventBigu+LinaGlin+LinaGlit+LinaSU+LinaA-GI+LinaSU+MetA-GI+Met
Benign prostatic hyperplasiaReproductive system and breast disorders0/820/660/740/1432/850/630/61
PneumoniaInfections and infestations0/820/660/740/1431/850/631/61
CataractEye disorders0/820/660/741/1430/850/631/61
Vertigo positionalEar and labyrinth disorders0/820/660/740/1430/850/631/61
Gastroenteritis viralInfections and infestations0/820/660/740/1430/851/630/61
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/820/660/740/1430/851/630/61
Cerebral infarctionNervous system disorders1/820/660/740/1430/851/630/61
Cholecystitis acuteHepatobiliary disorders0/820/660/740/1430/851/630/61
CholelithiasisHepatobiliary disorders0/820/660/740/1430/851/630/61
Thermal burnInjury, poisoning and procedural complications0/820/660/740/1430/851/630/61
Most frequent other events
Showing 10 of 15
Most frequent other events
EventBigu+LinaGlin+LinaGlit+LinaSU+LinaA-GI+LinaSU+MetA-GI+Met
NasopharyngitisInfections and infestations30/8230/6625/7445/14335/8513/6327/61
HypoglycaemiaMetabolism and nutrition disorders0/820/662/7420/1431/8510/632/61
BronchitisInfections and infestations9/821/661/745/1433/851/633/61
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders4/822/666/744/1433/850/636/61
ContusionInjury, poisoning and procedural complications4/822/661/7410/1432/851/635/61
PharyngitisInfections and infestations5/825/663/745/1432/852/630/61
FallInjury, poisoning and procedural complications4/823/661/7410/1433/851/634/61
GastroenteritisInfections and infestations2/821/662/744/1434/854/631/61
CoughRespiratory, thoracic and mediastinal disorders1/820/661/740/1431/854/630/61
ConstipationGastrointestinal disorders3/823/662/744/1435/854/631/61

Baseline characteristics

Age, Customized
Age, Customized(years)Bigu+LinaGlin+LinaGlit+LinaSU+LinaA-GI+LinaSU+MetA-GI+MetTotal
Mean58.4 ± 9.962.6 ± 8.860.4 ± 9.461.8 ± 10.862.0 ± 10.461.2 ± 10.659.3 ± 10.360.9 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Bigu+LinaGlin+LinaGlit+LinaSU+LinaA-GI+LinaSU+MetA-GI+MetTotal
Female33181638301919173
Male494858105554442401
08

Study locations

43 sites
  • 1218.78.008 Boehringer Ingelheim Investigational Site
    Akishima, Tokyo, Japan
  • 1218.78.030 Boehringer Ingelheim Investigational Site
    Amagasaki, Hyogo, Japan
  • 1218.78.017 Boehringer Ingelheim Investigational Site
    Annaka, Gunma, Japan
  • 1218.78.006 Boehringer Ingelheim Investigational Site
    Aomori, Aomori, Japan
  • 1218.78.007 Boehringer Ingelheim Investigational Site
    Aomori, Aomori, Japan
  • 1218.78.009 Boehringer Ingelheim Investigational Site
    Chuo-ku, Tokyo, Japan
  • 1218.78.013 Boehringer Ingelheim Investigational Site
    Chuo-ku, Tokyo, Japan
  • 1218.78.032 Boehringer Ingelheim Investigational Site
    Fukuoka, Fukuoka, Japan
  • 1218.78.040 Boehringer Ingelheim Investigational Site
    Fukuoka, Fukuoka, Japan
  • 1218.78.037 Boehringer Ingelheim Investigational Site
    Higashi Osaka, Osaka, Japan
  • 1218.78.043 Boehringer Ingelheim Investigational Site
    Hitachinaka, Ibaraki, Japan
  • 1218.78.019 Boehringer Ingelheim Investigational Site
    Isesaki, Gunma, Japan
  • 1218.78.036 Boehringer Ingelheim Investigational Site
    Kashiwara, Osaka, Japan
  • 1218.78.026 Boehringer Ingelheim Investigational Site
    Kasugai, Aichi, Japan
  • 1218.78.038 Boehringer Ingelheim Investigational Site
    Kawachinagano, Osaka, Japan
  • 1218.78.021 Boehringer Ingelheim Investigational Site
    Kitaazumi-gun, Nagano, Japan
  • 1218.78.022 Boehringer Ingelheim Investigational Site
    Matsumoto, Nagano, Japan
  • 1218.78.033 Boehringer Ingelheim Investigational Site
    Matsumoto, Nagano, Japan
  • 1218.78.012 Boehringer Ingelheim Investigational Site
    Meguro-ku, Tokyo, Japan
  • 1218.78.041 Boehringer Ingelheim Investigational Site
    Meguro-ku, Tokyo, Japan
  • 1218.78.034 Boehringer Ingelheim Investigational Site
    Morioka, Iwate, Japan
  • 1218.78.035 Boehringer Ingelheim Investigational Site
    Morioka, Iwate, Japan
  • 1218.78.018 Boehringer Ingelheim Investigational Site
    Moriya, Ibaraki, Japan
  • 1218.78.024 Boehringer Ingelheim Investigational Site
    Nagoya, Aichi, Japan
  • 1218.78.025 Boehringer Ingelheim Investigational Site
    Nagoya, Aichi, Japan
  • 1218.78.027 Boehringer Ingelheim Investigational Site
    Nagoya, Aichi, Japan
  • 1218.78.028 Boehringer Ingelheim Investigational Site
    Nagoya, Aichi, Japan
  • 1218.78.031 Boehringer Ingelheim Investigational Site
    Nagoya, Aichi, Japan
  • 1218.78.039 Boehringer Ingelheim Investigational Site
    Oita, Oita, Japan
  • 1218.78.004 Boehringer Ingelheim Investigational Site
    Okinawa, Okinawa, Japan
  • 1218.78.016 Boehringer Ingelheim Investigational Site
    Sagae, Yamagata, Japan
  • 1218.78.001 Boehringer Ingelheim Investigational Site
    Sapporo, Hokkaido, Japan
  • 1218.78.020 Boehringer Ingelheim Investigational Site
    Sapporo, Hokkaido, Japan
  • 1218.78.042 Boehringer Ingelheim Investigational Site
    Sapporo, Hokkaido, Japan
  • 1218.78.005 Boehringer Ingelheim Investigational Site
    Shimajiri-gun, Okinawa, Japan
  • 1218.78.014 Boehringer Ingelheim Investigational Site
    Shinjuku-ku, Tokyo, Japan
  • 1218.78.002 Boehringer Ingelheim Investigational Site
    Shinjyuku-ku. Tokyo, Japan
  • 1218.78.011 Boehringer Ingelheim Investigational Site
    Shizuoka, Shizuoka, Japan
  • 1218.78.003 Boehringer Ingelheim Investigational Site
    Suita, Osaka, Japan
  • 1218.78.023 Boehringer Ingelheim Investigational Site
    Tokorozawa, Saitama, Japan
  • 1218.78.029 Boehringer Ingelheim Investigational Site
    Tokorozawa, Saitama, Japan
  • 1218.78.010 Boehringer Ingelheim Investigational Site
    Tsuchiura, Ibaraki, Japan
  • 1218.78.015 Boehringer Ingelheim Investigational Site
    Yamagata, Yamagata, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2010
First posted
Sep 17, 2010
Start
Sep 2010
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
Jan 23, 2013
Last update
Mar 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01204294
Responsible party
Sponsor
First posted
Sep 17, 2010
Start date
Sep 2010
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Jan 23, 2013
Last update
Mar 28, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion